Key facts
- Astek Diagnostics’s last known valuation is $17.0M (Mar 2024).
- It has raised $6.5M across 5 recorded rounds; the latest was Seed Round ($750K) in Apr 2025.
- Notable investors include Y Combinator, US National Science Foundation, MedTech Innovator, National Institutes of Health, TEDCO — 20 tracked in total.
- Astek Diagnostics has filed 8 Form Ds with the SEC since 2023, most recently Apr 2025 ($750K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Astek Diagnostics
Funding rounds
5 roundsAbout Astek Diagnostics
Developer of a precision diagnostic technology designed to determine the existence of bacteria in the urine. The company's device employs a single-use cartridge to identify bacterial infection in the urine in less time than usual by detecting the oxygen consumption of bacterial species, enabling patients to fight antibiotic resistance through susceptibility testing.
- Sector
- Healthcare
- HQ
- Halethorpe, MD, United States
- Founded
- 2020
- Employees
- 4
- Website
- astekdx.com/
- Ownership
- Privately Held (backing)
Astek Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Astek Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Astek Diagnostics in its N-PORT filings yet. We sweep new filings monthly.